Critical Appraisal of Asthma Study: NPY and Airway Hyperresponsiveness

This report presents a critical appraisal of a research study investigating the mechanisms underlying airway hyperresponsiveness (AHR) in asthma. The study focuses on the role of epithelium-generated neuropeptide Y (NPY) and its impact on airway smooth muscle contraction. The researchers found that the loss of transcription factors Foxp1 and Foxp4 in airway epithelial cells leads to increased NPY expression, which subsequently triggers AHR through the activation of smooth muscle. The study utilized various methods, including lung resistance and airway consistency testing, microarray analysis, and the examination of mouse models. The findings suggest that targeting epithelial acceptance of this phenotype may prove beneficial in treating non-eosinophilic asthma. The report highlights the strengths of the study, such as its novel findings linking a specific transcription pathway in airway epithelium to AHR, and discusses its implications for potential asthma treatments. The study also acknowledges the limitations, such as the lack of changes in airway smooth muscle in Foxp1/4DKO mutants. The study's conclusion is supported by data showing that the loss of Foxp1 and Foxp4 induced AHR without inspiring airway eosinophilic aggravation. The study also found that NPY advances Rho kinase movement without anyone else and in collaboration with BK as measured by Western smear. The report concludes that NPY is a key signaling molecule and neurotransmitter, and its role in asthma is significant, potentially opening avenues for new therapeutic interventions.

Critical Appraisal of “Epithelium-generated neuropeptide y induced smooth
muscle contraction to promote airway hyperresponsiveness”

Background and aim of the study:
Asthma is a widely spread chronic health problem that grows enormously and can be categorized into
with or without an immune interaction like either illness including a Th2 inflammatory or eosinophilic
insusceptible reaction or malady lacking eosinophilic contribution. Recent treatments have little
impact on nonimmune illness, and the mechanisms that control this kind of asthma are inadequately
known. The present paper demonstrated that the basic airway transcription factors (epithelial)
forkhead box P1 (FOXP1) and FOXP4 act equivalently to inhibit expression of neuropeptide Y
(NPY), particularly in the airway of epithelium. Essentially, loss of FOXP1 and FOXP4 prompts
expanded NPY expression that can, thusly, actuate airway hyperreactivity in a paracrine way through
the enactment of smooth muscle myosin light-chain phosphorylation. Together, the study highlights
the significance of paracrine signs from the airway epithelium to the fundamental smooth muscle to
instigate AHR and recommend that treatments focusing on epithelial acceptance of this phenotype
may demonstrate helpful in the treatment of noneosinophilic asthma (Li et al., 2012).
Methods used to investigate the aim:
To investigate the part of the aviation route epithelium in asthma, they performed lung resistance and
aviation route consistency testing after the presentation to methacholine (Mch) on grown-up control
(Scgb1a1-Cre) and Scgb1a1-Cre: Foxp1flox/flox: Foxp4flox/flox (Foxp1/4DKO) mutants, and did
bigger proximal air route microarray examination, separately.
To survey whether the interruption of airway epithelial homeostasis brought on by loss of Foxp1 and
Foxp4 evoked AHR, a characterizing phenotype of asthma, study accomplished lung resistance and
airway consistency testing after presentation to methacholine on grown-up controls (Scgb1a1-Cre)
and Scgb1a1-Cre Foxp1fl/fl Foxp4fl/fl (in this alluded to as Foxp1/4DKO) mutants. To establish the
relationship among the genotype and lung resistance R package lme4 was performed for the analysis
of linear mixed effects (Douwes, et al., 2002 and Bates et al., 2014)). Era and genotyping of
Foxp1fl/fl, Foxp4fl/fl, Scgb1a1-Cre, and Npy–/ – mouse lines have been beforehand announced (Li et
al., 2012; Erickson et al., 1996). The mouse lines were continued a blended foundation comprising

of C57BL/6 and 129SvJ. Control creatures were gotten from a similar foundation and, when
conceivable, indistinguishable litter from the mutant creatures (Li et al., 2012).
Results:
Loss of the translation elements forkhead box P1 (Foxp1) and Foxp4, which are basic for
lung epithelial advancement, in the grown-up aviation route epithelium summons a non-Th2
asthma phenotype that is described via aviation route hyperresponsiveness (AHR) without
eosinophilic aggravation. Transcriptome examination uncovered that loss of Foxp1 and
Foxp4 expression prompts ectopic articulation of neuropeptide Y (Npy), which has been
accounted for to be available in the aviation routes of asthma patients, yet whose significance
in ailment pathogenesis stays vague. Treatment of human lung aviation route explants with
recombinant NPY expanded aviation route contractility. On the other hand, loss of Npy in
Foxp1-and Foxp4-mutant aviation route epithelium saved the AHR phenotype. We verified
that NPY advances AHR through the acceptance of Rho kinase action and phosphorylation of
myosin light chain, which instigates aviation route smooth muscle constriction.
This phenotype can likewise be initiated in mouse and human lung explants by treatment with
recombinant NPY, uncovering the significance of epithelial/smooth muscle paracrine
motioning in advancing the asthma phenotype in both mouse and human lungs (Li et al.,
2012).
The conclusion in accordance with data:
Lung imperviousness to combined dosages of methacholine was calculated. Lack in FOXP1
and FOXP4 in epithelial cells notably improves methacholine-incited lung resistance shown
in aviation route resistance (RL) and dynamic elastance (n = 6 for control and DKO,
separately) and in the mouse PCLS measure (control n = 9, 30 cuts; DKO n = 8, 19 cuts).
Loss of Foxp1 and Foxp4 instigated AHR without inspiring aviation route eosinophilic

aggravation, as shown by no huge increment in IL-13, IL-17 (n = 11 for control, 8 for DKO),
IL-6, and KC (n = 3 for WT and 4 for DKO, individually) Heat delineate the microarray
examinations demonstrating that Npy expression was expanded by in the emitted proteins
class in Foxp1/4DKO mutants. ISH indicating expanded Npy expression in the epithelium of
Foxp1/4DKO mutants.
Pretreatment with NPY especially improves maximal bronchoconstriction initiated by
methacholine. NPY treatment alone has little impact on pMLC; in any case, pretreatment
with NPY especially upgrades methacholine-actuated pMLC. NPY had little impact on
pinnacle calcium levels prompted by contractile agonists BK or histamine, showing that NPY
does not act to incite calcium preparation through these 2 pathways. NPY advances Rho
kinase movement without anyone else and in collaboration with BK as measured by Western
smear.
Loss of Npy expression protects the AHR phenotype in Foxp1/4DKO mutants and embroils
an epithelial/stromal flagging pathway managing AHR. The aviation route epithelium of
Foxp1/4DKO mutants contains substantial flagon like cells with decreased articulation of
markers of separated club secretory cells, including Scgb1a1. Articulation of Scgb1a1 was
incompletely safeguarded in the Foxp1/4 NpyTKO mutants. Conversely, articulation of
numerous challis cell markers that were raised in the Foxp1/4DKO mutants was not changed
by the extra loss of Npy expression (Li et al., 2012).
Contribution:
NPY is a flagging particle and neurotransmitter discovered bounteously in the sensory system
and some different parts of the body. Its numerous natural activities incorporate animating the
narrowing of veins. The group demonstrated that NPY has a noteworthy part in asthma by
erasing the NPY quality while in the meantime erasing the Foxp1/4 qualities. The specialists

tried whether NPY could specifically bring about aviation route hyperresponsiveness in
human lung tissue. These examinations demonstrated that when ordinary human lung
aviation routes are presented to NPY, they display a checked increment in hyper-
responsiveness to methacholine challenge.
Strengths and Weakness:
Expanded articulation of Npy in aviation route epithelium can initiate an AHR phenotype in a
paracrine way. Vitally, these reviews are among the, to begin with, as far as anyone is
concerned, to unthinkingly connect a basic translation pathway in aviation route epithelium
that enacts a paracrine reaction to the advancement of AHR without a Th2-actuated
eosinophilic incendiary reaction. Hindering NPY movement in individuals with asthma,
maybe with a breathed in prescription, may help the large number of patients who get
practically no advantage from current asthma treatments (University of Pennsylvania School
of Medicine, 2016).
Expanded Npy expression is related to a mouse model of unfavorably susceptible aviation
route irritation, and polymorphisms in the Npy quality are related to an expanded danger of
asthma (Jaakkola et al., 2012; Makinde et al., 2013). Appraisal of changes in the measure of
airway smooth muscle in Foxp1/4DKO mutants did not uncover any progressions contrasted
and control.

References:
 Douwes, J., Gibson, P., Pekkanen, J., & Pearce, N. (2002). Non-eosinophilic asthma:
importance and possible mechanisms. Thorax, 57(7), 643-648.
 Bates, D., Mächler, M., Bolker, B., & Walker, S. (2014). Fitting linear mixed-effects
models using lme4. arXiv preprint arXiv:1406.5823.
 Li, S., Wang, Y., Zhang, Y., Lu, M. M., DeMayo, F. J., Dekker, J. D., ... & Morrisey,
E. E. (2012). Foxp1/4 control epithelial cell fate during lung development and
regeneration through regulation of anterior gradient 2. Development, 139(14), 2500-
2509.
 Erickson, J. C., Clegg, K. E., & Palmiter, R. D. (1996). Sensitivity to leptin and
susceptibility to seizures of mice lacking neuropeptide Y. Nature, 381(6581), 415.
 Jaakkola, U., Kakko, T., Juonala, M., Lehtimäki, T., Viikari, J., Jääskeläinen, A. E., ...
& Raitakari, O. (2012). Neuropeptide Y polymorphism increases the risk for asthma
in overweight subjects; protection from atherosclerosis in asthmatic subjects–the
cardiovascular risk in young Finns study. Neuropeptides, 46(6), 321-328.
 Makinde, T. O., Steininger, R., & Agrawal, D. K. (2013). NPY and NPY receptors in
airway structural and inflammatory cells in allergic asthma. Experimental and
molecular pathology, 94(1), 45-50.
 University of Pennsylvania School of Medicine. (2016, April 19). New pathway that
may trigger asthma discovered: Finding could lead to better drugs for the many
asthma patients who don't respond well to current medications. ScienceDaily.
Retrieved May 20, 2017 from
www.sciencedaily.com/releases/2016/04/160419081706.htm